Illustrative image – not actual.Cadila Pharmaceuticals (CPL), will invest Rs 100 crore for expansion, upgradation and modernisation of its manufacturing unit at Samba in Jammu district of Jammu & Kashmir.
The project is spread over 11 acre. The company had already commenced Phase-I commercial production at this unit in 2006 with an initial investment of Rs 100 crore, and now manufactures 140 drugs.
Apart from this, the company has also proposed to develop a similar unit at Udaipur in Rajasthan over 40 acre, with an investment of Rs 150 crore. For the project, the company is awaiting environmental clearance.
Meanwhile, Cadila Pharmaceuticals is also bracing to enter the US market with 10 products in FY15.
